While I am not necessarily predicting any of these in the short term (ie., the next 2-4 weeks), I think many of these will happen over the next few months.
1. Favorable Peer reviewed clinical data on Flint Study is released. 2. Favorable Peer reviewed clinical data of Thyroid Study (ASAP) is released. 3. New Anatabine human clinical trials are announced for other ailments such as MS, Parkinson's, Cancer, Autism, etc. 4. Johns Hopkins announces new (or expanded) studies on Anatabine (this will completely discredit the basis for the Class Action suits and reveal that those class action law firms did not do their due diligence before filing suits). 5. Class Action suit(s) could be dropped or dismissed by the court (Note: this may not happen until after the lead plaintiff/law firm is determined by the courts). 6. Doctors who have been involved in human clinical trials start appearing on medical TV and/or Radio shows after the initial clinical trial results are released. We could see more Doctors talking to the press ...like this. 7. One of the tobacco companies decides they need Star's patents because of the new Tobacco labeling requirement which requires TSNA Carcinogen levels to be printed on the labels (both NNK and NNN content muct be on all tobacco product labels). http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297752.htm 8. A big Pharma company signs some sort of partnership or teaming arrangement witrh STSI 9. One or more professional teams (Football, Baseball, or Basketball) start providing Anatabloc to their players and sign an agreement with Star. 10. The veterinary product line of Anatabloc is launched (we saw that was coming when they trademarked "Anatapup"). 11. A major drugstore (CVS, Walgreens, etc.) or a major store chain (Walmart, Target, etc.) starts distributing Anatabloc 12. Someone initiates a hostile (or friendly) takeover attempt. 13. A well known big fish files a 13-D or 13-G (Icahn, Buffett, etc.) 14. Successful early results in the Rosacia or Alzheimer's clinical trial are reported. 15. A large institution or hedge fund starts to take a big position ( a few million shares) and initiates a short squeeze.
Well....you get the idea. There are dozens of potential catalysts that are more related to the science of how Anatabine stops the activation of NF-kB and can be used to treat a variety of diseses associated with chronic inflammation. Those of us who take it know it works on a variety of autoimmune related diseases. For example, after adjusting my own dosage levels, I no longer take Humira or Methotrexate for my RA.
On the other hand, we may see another short attack like we saw in Feb. I will be buying the dips if some BS piece of negative news comes out.
One of these days, the world will understand what we already know on this board.
Market Data 
Markets 
AI
